
Organogenesis Holdings (ORGO) Stock Forecast & Price Target
Organogenesis Holdings (ORGO) Analyst Ratings
Bulls say
Organogenesis Holdings is a strong player in the regenerative medicine sector, with a diverse portfolio of advanced wound care and sports medicine products. While changes in reimbursement policies and competition pose challenges, ORGO's success in clinical studies and recent positive results for ReNu show their potential for growth. Their efforts to address billing concerns and improve revenue through a wastage reduction program demonstrate a proactive approach to overcoming market challenges.
Bears say
Organogenesis Holdings is currently facing challenges in the advanced wound care market due to a decline in pricing, which is expected to result in a significant decline in the first quarter of 2026. While the company has a strong portfolio and is already seeing improvements in unit volumes, it may take longer for the market to normalize and fully understand the impact of the updated wastage policy. Despite a Buy rating and a $9 PT, the company's performance has been mixed and may improve as it achieves milestone progress and potential market consolidation occurs.
This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.
Organogenesis Holdings (ORGO) Analyst Forecast & Price Prediction
Start investing in Organogenesis Holdings (ORGO)
Order type
Buy in
Order amount
Est. shares
0 shares